June 2026– date –
-
Beam Therapeutics Stock Rises 2.04% After Receiving Triangle Business Journal’s 2026 Life Sciences Award, Signaling Heightened Market Optimism
Traders Union USA Overview Beam Therapeutics received the prestigious 2026 Life Sciences Award from Triangle Business Journal, acknowledging its innovative contributions. Concurrently, the company's stock experienced a 2.04% rise, reflec... -
High Volume of CRISPR Therapeutics Call Options Reflects Strong Market Confidence in Gene-Editing Pipeline
MarketBeat USA Overview On June 4, 2026, CRISPR Therapeutics (NASDAQ:CRSP) experienced exceptionally high call option trading volume, indicating robust investor interest in the company. This active trading reflects sustained confidence f... -
Intellia Therapeutics to Unveil Additional Phase 3 HAELO Data for Lonvo-z, a Hereditary Angioedema Therapy, at EAACI Annual Congress
Quiver Quantitative USA Overview Intellia Therapeutics announced it would present additional Phase 3 HAELO clinical trial data for lonvo-z (lonvoguran ziclumeran), its CRISPR-based gene-editing therapy for hereditary angioedema (HAE), at... -
Fate Therapeutics’ iPSC-Derived CAR T Therapy FT836 Shows Tumor Reduction and Favorable Safety Profile in KRASwt Colorectal Cancer Phase 1 Data at ASCO
GlobeNewswire (Fate Therapeutics Press Release) USA Overview Fate Therapeutics presented preliminary Phase 1 clinical data for its iPSC-derived, off-the-shelf CAR T-cell therapy, FT836, at the 2026 American Society of Clinical Oncology (... -
Vyjuvek Secures UK MHRA Approval; REGENXBIO’s RGX-202 Achieves Primary Endpoint in Duchenne Muscular Dystrophy Phase 3 Trial
YouTube (Lucid Quest) USA Overview A May 28, 2026, update reported that Vyjuvek, a gene therapy for dystrophic epidermolysis bullosa, has received UK MHRA approval. Concurrently, REGENXBIO's RGX-202, a gene therapy for Duchenne muscular ... -
EMA Initiates Review of Otarmeni’s Hereditary Hearing Loss Gene Therapy; Eli Lilly Announces Phase 2 Plans for VERVE-102 in Cardiovascular Disease
LucidQuest Ventures USA Overview Key developments in the cell and gene therapy sector were reported on May 28, 2026, with Otarmeni's hereditary hearing loss gene therapy entering EMA review. Eli Lilly detailed its Phase 2 clinical trial ... -
CRISPR Therapeutics to Detail Broadening Gene-Editing Pipeline at June Investor Conferences, Highlighting Approved Casgevy and Multidisease Programs
Market Chameleon USA Overview CRISPR Therapeutics announced plans to present its expanding gene-editing pipeline at three major investor conferences in early June 2026. The company will discuss the commercial progress of its approved gen... -
Tempus AI and Roswell Park Unveil Groundbreaking AI Algorithms for Pancreatic Cancer and Metastatic RCC at ASCO 2026
Tempus 他 USA Overview At the 2026 ASCO Annual Meeting, Tempus AI and Roswell Park Comprehensive Cancer Center announced significant advancements in AI-driven oncology, showcasing novel algorithms designed to revolutionize cancer diagnos... -
Evolution of Leading Generative AI Foundation Models: Google Gemini 3.5 Flash and Anthropic Claude Opus 4.8 Series Emerge
Amquest Education India Overview As of mid-2026, leading generative AI foundation models include Google DeepMind's Gemini 3.5 Flash and Gemini 3.1 Pro, noted for their native multimodal capabilities and competitiveness against GPT-5 clas... -
OpenAI and Anthropic Dominate AI Revenue, with Anthropic Approaching $30B Annually, as Information Disclosure Asymmetry Becomes Industry Challenge
PR Newswire USA Overview The 2026 AI Company Comms Study by 5WPR reveals that OpenAI and Anthropic are dominating AI revenue, with Anthropic's annualized revenue reaching approximately $30 billion in April 2026, surpassing OpenAI's $25 b...
